These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 23046235)

  • 1. siRNA and cancer immunotherapy.
    Ghafouri-Fard S; Ghafouri-Fard S
    Immunotherapy; 2012 Sep; 4(9):907-17. PubMed ID: 23046235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapeutic strategies employing RNA interference technology for the control of cancers.
    Mao CP; Hung CF; Wu TC
    J Biomed Sci; 2007 Jan; 14(1):15-29. PubMed ID: 17103251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Silencing or stimulation? siRNA delivery and the immune system.
    Whitehead KA; Dahlman JE; Langer RS; Anderson DG
    Annu Rev Chem Biomol Eng; 2011; 2():77-96. PubMed ID: 22432611
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dendritic cell immunotherapy for the treatment of neoplastic disease.
    Decker WK; Xing D; Shpall EJ
    Biol Blood Marrow Transplant; 2006 Feb; 12(2):113-25. PubMed ID: 16443510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dendritic cells as natural adjuvants and modulators of immune response in cancer immunotherapy.
    Alli RS; Khar A
    Indian J Biochem Biophys; 2002 Dec; 39(6):363-7. PubMed ID: 22905392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer immunogene therapy.
    Yoshizawa H; Kagamu H; Gejyo F
    Arch Immunol Ther Exp (Warsz); 2001; 49(5):337-43. PubMed ID: 11798131
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RNA pulsed dendritic cells: an approach for cancer immunotherapy.
    Garg NK; Dwivedi P; Prabha P; Tyagi RK
    Vaccine; 2013 Feb; 31(8):1141-56. PubMed ID: 23306369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DCs and CD40-activated B cells: current and future avenues to cellular cancer immunotherapy.
    Schultze JL; Grabbe S; von Bergwelt-Baildon MS
    Trends Immunol; 2004 Dec; 25(12):659-64. PubMed ID: 15530836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetically modified dendritic cells in cancer immunotherapy: a better tomorrow?
    Shurin MR; Gregory M; Morris JC; Malyguine AM
    Expert Opin Biol Ther; 2010 Nov; 10(11):1539-53. PubMed ID: 20955111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dendritic cells and their role in cancer immunotherapy.
    Jalili A
    Iran J Immunol; 2007 Sep; 4(3):127-44. PubMed ID: 17767012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overcoming the challenges of siRNA activation of innate immunity: design better therapeutic siRNAs.
    Sioud M
    Methods Mol Biol; 2015; 1218():301-19. PubMed ID: 25319660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dendritic cell engineering for tumor immunotherapy: from biology to clinical translation.
    Bhargava A; Mishra D; Banerjee S; Mishra PK
    Immunotherapy; 2012 Jul; 4(7):703-18. PubMed ID: 22853757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in specific immunotherapy for prostate cancer.
    Kiessling A; Füssel S; Wehner R; Bachmann M; Wirth MP; Rieber EP; Schmitz M
    Eur Urol; 2008 Apr; 53(4):694-708. PubMed ID: 18061335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biological properties of dendritic cells: implications to their use in the treatment of cancer.
    van Schooten WC; Strang G; Palathumpat V
    Mol Med Today; 1997 Jun; 3(6):254-60. PubMed ID: 9211416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The promise of 4-1BB (CD137)-mediated immunomodulation and the immunotherapy of cancer.
    Lynch DH
    Immunol Rev; 2008 Apr; 222():277-86. PubMed ID: 18364008
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Dendritic cells: orchestration of the immune response].
    Martinon-Ego C; Berthier R
    Ann Biol Clin (Paris); 2000; 58(5):541-56. PubMed ID: 11022098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances in siRNA delivery to T-cells: potential clinical applications for inflammatory disease, cancer and infection.
    Freeley M; Long A
    Biochem J; 2013 Oct; 455(2):133-47. PubMed ID: 24070422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chimeric antigen receptors in cancer immuno-gene therapy: current status and future directions.
    Chicaybam L; Sodré AL; Bonamino M
    Int Rev Immunol; 2011; 30(5-6):294-311. PubMed ID: 22053970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune monitoring of cancer patients undergoing experimental immunotherapy.
    Shankar G; Salgaller ML
    Curr Opin Mol Ther; 2000 Feb; 2(1):66-73. PubMed ID: 11249653
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Active specific T-cell-based immunotherapy for cancer: nucleic acids, peptides, whole native proteins, recombinant viruses, with dendritic cell adjuvants or whole tumor cell-based vaccines. Principles and future prospects.
    Fernandez N; Duffour MT; Perricaudet M; Lotze MT; Tursz T; Zitvogel L
    Cytokines Cell Mol Ther; 1998 Mar; 4(1):53-65. PubMed ID: 9557217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.